Mar 08th 2013 - Edison Investment Research today published a report on Pharmaxis entitled "Rethinking Bronchitol". In summary, the report says:
Pharmaxis is set to release results of a large Phase III trial of Bronchitol (inhaled mannitol) in non-cystic fibrosis bronchiectasis in Q2, which could mark a turning point after its recent travails. Pharmaxis has seen its share price fall heavily (c 65%) in the wake of the negative US FDA advisory committee review of Bronchitol in cystic fibrosis (CF) in January. However, its recent US$40m financing allows it to continue development of Bronchitol for CF/non-CF uses in the US and EU.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
